| Human immunodeficiency virus I infection
Fuzeon vs Odefsey
Side-by-side clinical, coverage, and cost comparison for human immunodeficiency virus i infection.Deep comparison between: Fuzeon vs Odefsey with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsOdefsey has a higher rate of injection site reactions vs Fuzeon based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Odefsey but not Fuzeon, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Fuzeon
Odefsey
At A Glance
SC injection
Twice daily
HIV-1 fusion inhibitor
Oral
Once daily
NRTI + NNRTI combination
Indications
- Human immunodeficiency virus I infection
- Human immunodeficiency virus I infection
Dosing
Human immunodeficiency virus I infection (Adults) 90 mg (1 mL) SC twice daily injected into the upper arm, anterior thigh, or abdomen.
Human immunodeficiency virus I infection (Pediatric, >=11 kg) 2 mg/kg SC twice daily up to a maximum of 90 mg twice daily injected into the upper arm, anterior thigh, or abdomen; adjust dose with weight changes.
Human immunodeficiency virus I infection One tablet (emtricitabine 200 mg, rilpivirine 25 mg, tenofovir alafenamide 25 mg) orally once daily with a meal
Contraindications
- Known hypersensitivity to enfuvirtide or any excipient of FUZEON
- Coadministration with carbamazepine
- Coadministration with oxcarbazepine
- Coadministration with phenobarbital
- Coadministration with phenytoin
- Coadministration with rifampin
- Coadministration with rifapentine
- Coadministration with dexamethasone (more than a single dose)
- Coadministration with St. John's wort
- Coadministration with proton pump inhibitors
Adverse Reactions
Most common Local injection site reactions (pain/discomfort, induration, erythema, nodules/cysts, pruritus, ecchymosis), diarrhea, nausea, fatigue, weight decreased, sinusitis, abdominal pain, cough, herpes simplex, appetite decreased, pancreatitis, pneumonia, myalgia
Serious Pneumonia, hypersensitivity reactions, renal failure, Guillain-Barre syndrome, thrombocytopenia, neutropenia, sepsis, toxic hepatitis, unstable angina pectoris
Postmarketing Cutaneous amyloidosis at the injection site
Most common (>=2%) Headache, sleep disturbances
Serious Severe acute exacerbations of hepatitis B, skin and hypersensitivity reactions, hepatotoxicity, depressive disorders, new onset or worsening renal impairment, lactic acidosis/severe hepatomegaly with steatosis, immune reconstitution syndrome
Postmarketing Weight increased, severe skin and hypersensitivity reactions including DRESS, nephrotic syndrome, angioedema, urticaria, rash, acute renal failure, acute tubular necrosis, proximal renal tubulopathy, Fanconi syndrome
Pharmacology
Enfuvirtide is an HIV-1 fusion inhibitor that binds to the first heptad-repeat (HR1) domain of the gp41 subunit of the viral envelope glycoprotein, preventing the conformational changes required for fusion of viral and cellular membranes and thereby blocking HIV-1 entry into CD4+ cells.
Odefsey is a fixed-dose combination of emtricitabine (an NRTI that inhibits HIV-1 reverse transcriptase by chain termination), rilpivirine (an NNRTI that non-competitively inhibits HIV-1 reverse transcriptase), and tenofovir alafenamide (a prodrug that is converted to tenofovir, an NRTI inhibiting HIV-1 reverse transcriptase by chain termination).
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Fuzeon
- Covered on 5 commercial plans
- PA (5/12) · Step Therapy (0/12) · Qty limit (1/12)
Odefsey
- Covered on 5 commercial plans
- PA (5/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Fuzeon
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (2/8) · Qty limit (2/8)
Odefsey
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (8/8)
Humana
Fuzeon
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (2/3)
Odefsey
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableGood Days: HIV, AIDS Treatment & Prevention
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
$0
Gilead Advancing Access Patient Assistance Program/Medication Assistance Program (PAP/MAP)Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
FuzeonView full Fuzeon profile
OdefseyView full Odefsey profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.